Lota S. Zoth - 21 Dec 2022 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: Director
Issuer ticker: ZYME
Reported as of: 21 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Dec 2022, 18:00:22 UTC
Prior SEC filing: 18 May 2022
Next SEC filing: 13 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Lota S. Zoth filed Form 4 for Zymeworks Inc. (ZYME) on 23 Dec 2022.

Key facts

This page summarizes Lota S. Zoth's Form 4 filing for Zymeworks Inc. (ZYME).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Dec 2022, 18:00.

Change

Previous filing in this sequence was filed on 18 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 21 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $8.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC remarks

Exhibit List - Exhibit 24 - Power of Attorney On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.